What are the treatment options for gustatory sweating in a 60-year-old patient with end-stage renal disease (ESRD) on chronic dialysis?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: March 17, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Guidelines

For a 60-year-old patient with end-stage renal disease on chronic dialysis, the treatment options for gustatory sweating are limited, and the primary focus should be on managing underlying conditions that may exacerbate symptoms, such as xerosis and uraemic pruritus, as there is no direct evidence for treating gustatory sweating in this population. The patient's condition is complex, and the treatment should prioritize minimizing morbidity, mortality, and improving quality of life. Given the lack of direct evidence for gustatory sweating treatment in ESRD patients, it's essential to consider the management of related conditions. According to the British Association of Dermatologists' guidelines 1, ensuring adequate dialysis, normalizing calcium-phosphate balance, controlling PTH levels, correcting anaemia with erythropoietin, and using emollients for xerosis are crucial steps before considering other treatment strategies. Some key points to consider in managing this patient include:

  • Ensuring adequate dialysis, with a suggested Kt/V of around 1.6, to minimize symptoms such as pruritus 1
  • Using emollients to manage xerosis, which is a common cutaneous sign in patients on dialysis 1
  • Considering the use of oral antihistamines, such as ketotifen or doxepin, for uraemic pruritus, but being cautious of potential side effects and the need for dose adjustment in renal failure 1
  • Monitoring for electrolyte imbalances and avoiding medications with significant renal clearance or those that might further compromise kidney function. It's crucial to weigh the potential benefits and risks of each treatment option and prioritize the patient's overall health and well-being.

From the FDA Drug Label

The FDA drug label does not answer the question.

From the Research

Treatment Options for Gustatory Sweating

  • The treatment options for gustatory sweating in a 60-year-old patient with end-stage renal disease (ESRD) on chronic dialysis are limited, but some studies suggest the following:
    • Topical glycopyrrolate may be safe and effective for treating gustatory sweating, as reported in a case study where a patient experienced recurrent gustatory sweating on peritoneal dialysis that resolved with hemodialysis 2.
    • Clonidine may also provide some relief, although it may not completely resolve symptoms 2.
  • It is essential to note that the management of gustatory sweating in patients with ESRD may be complex and require individualized treatment approaches.

Considerations for ESRD Patients

  • Patients with ESRD often experience various complications, including hyperkalemia, hypervolemia, metabolic acidosis, anemia, mineral and bone disorders, and protein-calorie malnutrition, which require careful management 3, 4.
  • Pain management is also crucial in ESRD patients, and opioids such as fentanyl and methadone may be considered safe for use in these patients 5, 6.
  • A palliative approach to ESRD may be a reasonable alternative to dialysis, particularly for individuals with limited life expectancy or severe comorbid conditions 4, 6.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Gustatory sweating recurring on peritoneal dialysis but resolving during periods of hemodialysis.

Hemodialysis international. International Symposium on Home Hemodialysis, 2008

Research

End-Stage Renal Disease: Medical Management.

American family physician, 2021

Research

Management of pain in end-stage renal disease patients: Short review.

Hemodialysis international. International Symposium on Home Hemodialysis, 2018

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.